Compare Microchip Technology Inc. (MCHP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Microchip Technology Inc. trades at $75.55 (market cap $41.01B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Microchip Technology Inc. is far larger — about 2.4× Zimmer Biomet Holdings Inc's market cap, and Microchip Technology Inc. pays the higher dividend (2.41%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MCHP | ZBH | |
|---|---|---|
Market Cap | $41.01B | $16.95B |
Volume | 9,972,516 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $102.97 | $103.98 |
52-Week Low | $49.02 | $79.58 |
Typical Hold Time | 63 Days | 89 Days |
Enterprise Value | $46.13B | $24.02B |
Dividend Yield | 2.41% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $75.52, down 3.2% over 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of -$500K in 2025, though it has beaten EPS estimates in recent quarters. Analyst consensus is strongly bullish with a $110.50 price target, supported by positive news on product expansions in Ethernet and 48V power portfolios and the completion of the Hailo acquisition.
The outlook is mixed: strong analyst support and strategic expansions in high-growth areas like AI and automotive present upside, but high valuation ratios, significant debt, and recent profitability challenges pose risks. Investor sentiment is cautiously optimistic amid sector tailwinds.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
